{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T20:11:01Z","timestamp":1776802261303,"version":"3.51.2"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.pcad.2010.06.005","type":"journal-article","created":{"date-parts":[[2010,8,21]],"date-time":"2010-08-21T09:11:47Z","timestamp":1282381907000},"page":"140-148","source":"Crossref","is-referenced-by-count":33,"title":["Reversibility of Left Ventricular Dysfunction Resulting from Chemotherapy: Can This Be Expected?"],"prefix":"10.1016","volume":"53","author":[{"given":"Quinn S.","family":"Wells","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Lenihan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2010.06.005_bb0005","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMsa060185","article-title":"Chronic health conditions in adult survivors of childhood cancer","volume":"355","author":"Oeffinger","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2010.06.005_bb0010","first-page":"337","article-title":"Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study","volume":"a2467","author":"Driver","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.pcad.2010.06.005_bb0015","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2006.08.0499","article-title":"Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma","volume":"25","author":"Hanrahan","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pcad.2010.06.005_bb0020","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/ijc.10981","article-title":"Health profiles in 5836 long-term cancer survivors","volume":"104","author":"Schultz","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pcad.2010.06.005_bb0025","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention","volume":"102","author":"Albini","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.pcad.2010.06.005_bb0030","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200022040-00002","article-title":"Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention","volume":"22","author":"Pai","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.pcad.2010.06.005_bb0035","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1161\/01.CIR.0000133187.74800.B9","article-title":"Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management","volume":"109","author":"Yeh","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2010.06.005_bb0040","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2010.06.005_bb0045","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2010.06.005_bb0050","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","article-title":"Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics","volume":"118","author":"Chen","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2010.06.005_bb0055","series-title":"NCI Na","article-title":"Common Terminology Criteria for Adverse Events Version 4","author":"National Institute of Health and National Cancer Institute","year":"2009"},{"key":"10.1016\/j.pcad.2010.06.005_bb0060","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05759.x","article-title":"Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies","volume":"131","author":"Wouters","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pcad.2010.06.005_bb0065","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12012-007-0005-5","article-title":"Molecular and cellular mechanisms of anthracycline cardiotoxicity","volume":"7","author":"Chen","year":"2007","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.pcad.2010.06.005_bb0070","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1040-8428(97)10007-5","article-title":"Anthracycline-induced cardiotoxicity in children and young adults","volume":"27","author":"Giantris","year":"1998","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.pcad.2010.06.005_bb0075","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2010.06.005_bb0080","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pcad.2010.06.005_bb0085","doi-asserted-by":"crossref","first-page":"679","DOI":"10.4065\/83.6.679","article-title":"Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials","volume":"83","author":"Perez","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pcad.2010.06.005_bb0090","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2010.06.005_bb0095","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1002\/cncr.23460","article-title":"Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor","volume":"112","author":"Khakoo","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.pcad.2010.06.005_bb0100","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2007-01-070144","article-title":"Congestive heart failure is a rare event in patients receiving imatinib therapy","volume":"110","author":"Atallah","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pcad.2010.06.005_bb0105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nm0107-13a","article-title":"In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate\u2019","volume":"13","author":"Hatfield","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.pcad.2010.06.005_bb0110","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood.V68.5.1114.1114","article-title":"Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor","volume":"68","author":"Goldberg","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.pcad.2010.06.005_bb0115","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1345\/aph.1K359","article-title":"Monitoring of anthracycline-induced cardiotoxicity","volume":"42","author":"Jannazzo","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.pcad.2010.06.005_bb0120","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","article-title":"Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy","volume":"342","author":"Felker","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2010.06.005_bb0125","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.266.12.1672","article-title":"Cardiac toxicity 4 to 20 years after completing anthracycline therapy","volume":"266","author":"Steinherz","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2010.06.005_bb0130","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJM199103213241205","article-title":"Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood","volume":"324","author":"Lipshultz","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2010.06.005_bb0135","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","article-title":"Tyrosine kinases as targets for cancer therapy","volume":"353","author":"Krause","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2010.06.005_bb0140","first-page":"9","article-title":"Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity","volume":"27","author":"Chien","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1016\/j.pcad.2010.06.005_bb0145","unstructured":"Pfizer. Sutent (sunitinib) prescribing information. 2010."},{"key":"10.1016\/j.pcad.2010.06.005_bb0150","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/annonc\/mdn168","article-title":"Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate","volume":"19","author":"Telli","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pcad.2010.06.005_bb0155","doi-asserted-by":"crossref","unstructured":"Chintalgattu V, Ai D, Langley RR, et al. Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J Clin Invest;120:472-84.","DOI":"10.1172\/JCI39434"},{"key":"10.1016\/j.pcad.2010.06.005_bb0165","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1158\/1078-0432.CCR-09-0058","article-title":"Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment","volume":"15","author":"Maitland","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pcad.2010.06.005_bb0170","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa043681","article-title":"Adjuvant docetaxel for node-positive breast cancer","volume":"352","author":"Martin","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2010.06.005_bb0175","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/1097-0142(19850915)56:6<1361::AID-CNCR2820560624>3.0.CO;2-S","article-title":"Doxorubicin-induced congestive heart failure in adults","volume":"56","author":"Haq","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.pcad.2010.06.005_bb0180","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.healun.2004.12.108","article-title":"Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure","volume":"24","author":"Tallaj","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.pcad.2010.06.005_bb0185","doi-asserted-by":"crossref","first-page":"S797","DOI":"10.1161\/circ.118.suppl_18.S_797","article-title":"High mortality rates are associated with withdrawal of beta blockers and ACE inhibitors in chemotherapy-induced heart failure","volume":"118","author":"Shukla","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2010.06.005_bb0190","first-page":"115","article-title":"Beta-blockade in adriamycin-induced cardiomyopathy","volume":"6","author":"Noori","year":"2000","journal-title":"J Card Fail"},{"key":"10.1016\/j.pcad.2010.06.005_bb0195","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/annonc\/mdf132","article-title":"Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients","volume":"13","author":"Jensen","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pcad.2010.06.005_bb0200","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pcad.2010.06.005_bb0205","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.2005.04.9551","article-title":"Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience","volume":"24","author":"Guarneri","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pcad.2010.06.005_bb0210","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2007.11.0106","article-title":"Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility","volume":"25","author":"Telli","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pcad.2010.06.005_bb0215","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pcad.2010.06.005_bb0220","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1542\/peds.89.5.942","article-title":"Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group","volume":"89","author":"Steinherz","year":"1992","journal-title":"Pediatrics"},{"key":"10.1016\/j.pcad.2010.06.005_bb0225","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1159\/000227621","article-title":"Review of tests for monitoring doxorubicin-induced cardiomyopathy","volume":"53","author":"Ganz","year":"1996","journal-title":"Oncology"},{"key":"10.1016\/j.pcad.2010.06.005_bb0230","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1200\/JCO.2007.10.9777","article-title":"American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects","volume":"25","author":"Carver","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pcad.2010.06.005_bb0235","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2008.17.2627","article-title":"American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants","volume":"27","author":"Hensley","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pcad.2010.06.005_bb0240","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.11.013","article-title":"Focused update incorporated into the ACC\/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation","volume":"53","author":"Hunt","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2010.06.005_bb0245","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S0735-1097(03)01065-9","article-title":"ACC\/AHA\/ASE 2003 guideline update for the clinical application of echocardiography-summary article: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (ACC\/AHA\/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography)","volume":"42","author":"Cheitlin","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2010.06.005_bb0250","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jacc.2003.08.011","article-title":"ACC\/AHA\/ASNC guidelines for the clinical use of cardiac radionuclide imaging-executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (ACC\/AHA\/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging)","volume":"42","author":"Klocke","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2010.06.005_bb0255","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2007.14.8742","article-title":"Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?","volume":"26","author":"Ewer","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pcad.2010.06.005_bb0260","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0735-1097(99)00118-7","article-title":"Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort","volume":"33","author":"Vasan","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2010.06.005_bb0265","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ejheart.2006.09.007","article-title":"Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy","volume":"9","author":"Belham","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pcad.2010.06.005_bb0270","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2004.03.025","article-title":"How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30","volume":"22","author":"Fromme","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pcad.2010.06.005_bb0275","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/j.cardfail.2007.06.634","article-title":"Superior detection of cardiotoxicity during chemotherapy using biomarkers","volume":"13","author":"Lenihan","year":"2007","journal-title":"J Cardiac Failure"},{"key":"10.1016\/j.pcad.2010.06.005_bb0280","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1046\/j.1365-2796.2002.00951.x","article-title":"Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction","volume":"251","author":"Nousiainen","year":"2002","journal-title":"J Intern Med"},{"key":"10.1016\/j.pcad.2010.06.005_bb0285","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2010.06.005_bb0290","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2010.06.005_bb0295","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2010.06.005_bb0300","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2010.06.005_bb0305","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2010.06.005_bb0310","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1002\/cncr.21478","article-title":"Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone","volume":"104","author":"Nakamae","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.pcad.2010.06.005_bb0315","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1634\/theoncologist.2008-0112","article-title":"Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer","volume":"13","author":"Lenihan","year":"2008","journal-title":"Oncologist"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062010001106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062010001106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T23:01:12Z","timestamp":1685746872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062010001106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0033062010001106"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2010.06.005","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}